| Species |
Human |
| Protein Construction |
| Avi |
His |
SOST/Sclerostin (Gln24-Tyr213)_x000D_
Accession # Q9BQB4-1 |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized SOST/Sclerostin, His & Avi, Human at 0.5μg/ml (100μl/Well) on the plate can bind AntiSOST Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
24.2 kDa |
| Apparent Molecular Weight |
Due to glycosylation,the protein migrates to 28-40 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
SOST, also known as sclerostin, is a member of the cerberus/DAN family, a group of secreted glycoproteins characterized by a cysteine-knot motif. SOST is negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation. |
| Synonyms |
sclerostin; SOST; VBCHsclerosteosis; CDD; DAND6; SOST1; VBCH |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
